Dexamethasone implantation in birdshot chorioretinopathy – long-term outcome

Figures & data

Figure 1 Case 1 HVF (baseline and final visit) and macular OCT at baseline, relapse, and final visit; case 1 fundus photos at baseline, relapse, and final visit.

Abbreviations: HVF, Humphrey visual field; OCT, optical coherence tomography.

Figure 2 Case 2 HVF and macular OCT at baseline, relapse, and final visit; case 2 fundus photos at baseline visit and relapse.

Abbreviations: HVF, Humphrey visual field; OCT, optical coherence tomography.

Figure 3 Case 3 HVF (baseline) and macular OCT at baseline, relapse, and final visit.

Abbreviations: HVF, Humphrey visual field; OCT, optical coherence tomography.

Table 1 Demographics and clinical parameters

Patient	Age (years)	Gender	HLA status	DEX dates	Tmax on DEX	Number of DEX	Last FU	Study parameters	Baseline	Post implant 1	Post implant 2	Post implant 3	Post implant 4	Last FU	TM before DEX	TM last FU	DEX complications
Patient 1	55	Male	HLA A 29	First – October 2013 (OD), September 2013 (OS), second – April 2014 (OU)’, third – October 2014 (OU)’	19, 19	3 OD, 3 OS	August 2015	BCVA (OD, OS)	20/25, 20/50	20/20, 20/40	20/30, 20/70+2	20/20, 20/30	NA+	20/30, 20/60	CSA, PO Pred	MM, CSA	PSC OD
								IOP (OD, OS)	11, 11	19, 19	15, 15	13, 15	NA+	12, 13
								Inflammatory status (±)	Vitritis 2+ OU	Vitritis 1+ OU	Vitritis 1+ OD, haze OS	Vitritis 1+ OU	NA+	Quiet OU
								CMT (OD, OS)	359, 269	273, 262	na	289, 279	NA+	237, 227
								HVF (MD OD, OS)	–13.5, –14.5a	na	na	na	NA+	–9.35, –8.47
								NEI VFQ score	55.19	64.28			NA+	75.12
Patient 2	47	Male	HLA A 29	First – March 2014 (OU)’, second – July 2014 (OU)’, third – November 2014 (OU)’, fourth – March 2015 (OU)’	36, 22	4 OD, 4 OS	November 2016	BCVA (OD, OS)	20/25, 20/20	20/25, 20/25	20/25, 20/25	20/25, 20/25	20/25, 20/20	20/30, 20/25	None	MM	Oc HTN OU PSC OU
								IOP (OD, OS)	14, 18	16, 18	22, 24b	22, 24	36, 22	19, 17
								Inflammatory status (±)	Vitritis 2+ OU	Vitritis 1+ OU	Vitritis 1+ OU	Vitritis 1+ OU	Vitritis 1+ OU	Quiet OU
								CMT (OD, OS)	351, 332	305, 299	na	298, 296	302, 305	327, 314
								HVF (MD OD, OS)	–5.1, –2.5	na	na	na	–6.5, –4.8	–3.41, –1.85
								NEI VFQ score	75.34	93.56				85.41
Patient 3	46	Male	HLA A 29	October 2014 (OD), September 2014 (OS)	45,54	1 OD, 1 OS	August 2015	BCVA (OD, OS)	20/80, 20/80	20/40, 20/20	NA+	NA+	NA+	20/30, 20/40	PO Pred, subtenon kenalog OU, dorzolamide + timolol OU	MM, ADA	None
								IOP (OD, OS)	32, 29	45, 54	NA+	NA+	NA+	16, 16
								Inflammatory status (±)	Vitritis 2+ OU		NA+	NA+	NA+	1+ cell/haze
								CMT (OD, OS)	626, 491	347, 297	NA+	NA+	NA+	327, 295
								HVF (MD OD, OS)	–5.0, –7.0	–2.8, –3.9	NA+	NA+	NA+	na
								NEI VFQ score	40.37	83.6				93.23

Notes:

a 10-2 visual field preferred given central field involvement;

b timolol OU started, (OU)’ DEX both eyes approximately 2 weeks apart.

Abbreviations: ADA, adalimumab; BCVA, best-corrected visual acuity; CMT, central macular thickness; MD, mean defect; CSA, cyclosporine; DEX, dexamethasone implant; FU, follow-up; HVF, Humphrey visual field test; MM, mycophenolate mofetil; NA, not applicable; na, not available; NEI VFQ, National Eye Institute Visual Function Questionnaire-25; Oc HTN, ocular hypertension; PO Pred, oral prednisone; PSC, posterior subcapsular cataract.